Retatrutide - 6MG/2ML | Packaging: 6 mg, Primary Goal: Intensive fat reduction, Secondary Goal: Metabolic balance and glycemic control

New 🔥 Bestseller Free

Retatrutide 6MG/2ML – multi-target metabolic agonist

Retatrutide is a next-generation metabolic peptide with a combined mechanism (GLP-1/GIP/GCGR). It strongly controls appetite and lipolysis (fat breakdown), which makes it valuable for fat loss and preparation for competitions and events. It contributes to more stable energy levels and easier adherence to a diet. It is most effective when combined with structured strength training and sufficient protein intake.

0 reviews • Write a review

€ 110.00 (215.14лв)

Ex Tax: € 110.00 (215.14лв)

Qty

Add to Cart

Buy Now Question?

Add to Wish List

Ask a Question about this Product

Shipping

Secure and safe worldwide delivery! If the product is on stock - average delivery time is 2-3 days in Eastern Europe, 3-7 days in Western Europe and 1-3 weeks world wide!

Improved storage formula

Improved storage formula - increased stability and extended shelf life!

Quality Control & Tests

High-quality product! All peptides branded MyPeptid are produced in 100% laboratory conditions and have purity above 98%. Our products are tested at JINOSHIK, Analiza Białek and other independent, established laboratories with high standards!

Tags: Intensive fat reduction

Product information

What is Retatrutide (Retatrutide)?

This peptide simultaneously reduces the sensation of hunger, helps control blood glucose, and directs the body toward higher energy expenditure, which can result in a significant reduction in body weight in experimental and clinical settings.

The triple-agonist incretin signaling (GLP‑1R/GIPR/GCGR) defines the molecular class of the compound and explains why its effects encompass appetite, glycemia, and energy expenditure simultaneously; available public summary information can be reviewed on Wikipedia: Retatrutide.

Mechanism of action

Activation of GLP‑1R and GIPR modulates incretin-dependent regulation of glycemia and central satiety pathways, while agonism at GCGR can increase energy expenditure and lipid mobilization; the combination is considered a rational design for a stronger metabolic response compared with single/double agonists. For laboratory purposes this allows separate or combined testing of receptor-specific effects (e.g., using cell lines, cAMP reporter systems, and models of energy metabolism).

Clinical data

study name	population or experimental model	number of subjects or samples	duration	key observed outcomes
Phase 2 (obesity) – публикувани резултати	Adults with overweight/obesity	338	48 weeks	Mean change in body weight up to −24.2% (highest dose) versus −2.1% (placebo)

Source for the numerical clinical data: The New England Journal of Medicine (publication on retatrutide in obesity). Additional context on clinical development and the mechanistic framework: PubMed (reviews/original articles on GLP‑1/GIP/glucagon triagonists).

Laboratory setting | clinical setting

In the laboratory, retatrutide is used to validate receptor selectivity/efficacy, compare triple-agonist versus dual-agonist incretin designs, and for pharmacodynamic markers (cAMP, transcriptional responses, metabolic fluxes). In the clinical setting it remains within controlled trials and protocols; it is not intended for routine use outside approved regulatory frameworks.

Pharmacokinetics

Publicly available details on human PK are limited and depend on the specific protocol; when planning experiments dosing is typically once weekly with serial sampling for concentration–time profiles, as well as parallel PD endpoints (glucose, insulin, weight/energy expenditure).

Purity and formula

Retatrutide from MyPeptid provides a reliable basis for analytical verification and bioactivity testing, as it is over 99% pure (HPLC) and suitable for standardized research protocols.

Formula: C225H348N48O68

Note: Offered for educational and research purposes only (research-only), not for diagnostic or therapeutic use.